Cognition Therapeutics Inc., a clinical-stage biopharmaceutical company based on the South Side, is likely gearing up for its first day of public trading Friday, according to a listing on the Nasdaq.
The startup filed to go public in June and is looking to raise up to $50 million through the initial public offering. It expects to offer 3,350,000 shares at $11-$13.
The stock will start trading under the ticker symbol CGTX.
Cognition Therapeutics has initially focused on the development of a treatment for Alzheimer's disease but is also working on the discovery of small molecule therapeutics to target other age-related degenerative diseases and disorders, according to the company's SEC filings.
Alzheimer's disease afflicts about 6.2 million people in the United States, and the disease’s prevalence is expected to more than double by 2050, the company says. It expects the direct health care costs for patients with Alzheimer's disease or other forms of dementia exceeds $300 billion.
The company has been awarded more than $168 million in grants and financial support for its clinical trials, primarily from the National Institute of Aging, a division of the National Institutes of Health.
Read More
Cognition Therapeutics, founded in 2007, has 22 employees and executive offices in Purchase, N.Y.
Lauren Rosenblatt: lrosenblatt@post-gazette.com, 412-263-1565.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.